AcuraBio a New Level of Excellence
New investors: expanded services & technologies

Client News Update

Dr. Glenn Haifer and Ampersand Capital Partners Acquire Australian Biologics CDMO Luina Bio, Rebranding Company as AcuraBio

AcuraBio (formerly Luina Bio), has been acquired by biotech investor Dr. Glenn Haifer and Ampersand Capital Partners, a global healthcare private equity firm.

The rebranding of the company signifies an innovative new growth phase for AcuraBio. As part of the transaction, Dr. Haifer and Ampersand are bringing significant investment to the company, with a focus on expanding the organization to better serve customers. To fuel additional growth, AcuraBio is planning to increase production facility capacity, and is actively evaluating expansion into new service offerings and technological capabilities.

Dr. Haifer brings a wealth of experience to AcuraBio, as the former company Chairman and investor behind Australian biotech successes such as Agilex Biolabs and Avance Clinical. “We are very excited to be reinventing a company with such deep scientific experience,” said Dr. Haifer. “With our deep expertise and commitment to further investment, AcuraBio will be a leader in the APAC region for international biopharma clients attracted by the technology, scientific excellence, and innovation we will bring to the platform. I am excited to leverage Ampersand’s industry expertise as we take AcuraBio to the next level.”

Based in the US and with more than $3 billion of assets under management, Ampersand is exclusively focused on growth-oriented investments in the healthcare sector. Ampersand has previously partnered with leading CDMOs such as Brammer Bio, ArrantaBio, Vibalogics, and Genezen, and the firm is a highly experienced investor in the emerging therapeutics CDMO industry. David Anderson, General Partner at Ampersand, said “AcuraBio is strategically positioned in Australia to support international biopharma drug development. Australia has a strong reputation for clinical and scientific excellence which is the foundation to success for a company like AcuraBio. We are extremely pleased to be working with Dr. Haifer, who is a proven biotech investor and growth strategist with a real focus on client-centric service innovations.”

Read press release here

AcuraBio: Empowering Innovation in Emerging Therapeutics

The specific needs of your complex project require microbial biomanufacturing expertise.

A one-size-fits-all approach simply won’t work. For the technical expertise, adaptability, and personalized attention your intricate project demands, choose AcuraBio.

Our team has proven technical experience and an ability to adapt our systems and processes to our clients’ individual needs. We’ll embrace your project as our own and make it our priority while delivering it at the highest quality standards.

We’re as passionate about the science behind your project as we are about its success.

Choose AcuraBio for your microbial biomanufacturing needs

Your mission is to improve the health of patients who use your product, and our mission is to help you achieve that mission by making drug development and manufacturing easier for you. For the unique expertise to help you actualize your vision, there’s only one CDMO to trust.

The latest from AcuraBio